HRTX Heron Therapeutics Inc.

23.5
+0.78  (+3%)
Previous Close 22.72
Open 22.79
Price To Book 4.97
Market Cap 1837268799
Shares 78,181,651
Volume 1,056,470
Short Ratio
Av. Daily Volume 908,303

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review April 30, 2019.
HTX-011
Post operative pain
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
FDA additional approval allowing IV injection in addition to current IV infusion.
CINVANTI (HTX-019)
Prevention of chemotherapy-induced nausea and vomiting (CINV)
Phase 2 data released June 21, 2018. Primary endpoint met.
HTX-011
Total knee arthroplasty

Latest News

  1. 3 Promising Small Biotech Stocks to Watch
  2. What Kind Of Share Price Volatility Should You Expect For Heron Therapeutics, Inc. (NASDAQ:HRTX)?
  3. 4 Biotech Stocks With Major Catalysts in April
  4. Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management
  5. 77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy
  6. Report: Exploring Fundamental Drivers Behind Caesars Entertainment, Party City Holdco, Rowan Companies, TiVo, Heron Therapeutics, and Cimarex Energy — New Horizons, Emerging Trends, and Upcoming Developments
  7. Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
  8. Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push
  9. Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
  10. Heron Therapeutics: 4Q Earnings Snapshot
  11. Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
  12. Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference
  13. How Much Did Heron Therapeutics, Inc.’s (NASDAQ:HRTX) CEO Pocket Last Year?
  14. Heron Therapeutics Announces Retirement of Robert Rosen as President
  15. Today's Research Reports on Trending Tickers: Mylan and Heron Therapeutics
  16. New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
  17. Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
  18. 90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study
  19. Company News For Jan 2, 2019
  20. Heron Gains on Priority Review Designation for Pain Drug